Jefferies analyst Chris Howerton downgrades UroGen Pharma (NASDAQ:URGN) from Buy to Hold and lowers the price target from $35 to $10.
Inhibrx Announces European Medicines Agency Grants Orphan Drug Designation To INBRX-109 For The Treatment Of Chondrosarcoma
Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development and a strong emerging pipeline, today announced that the European Commission ("EC"), based on a positive opinion
